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A B S T R A C T
The aim of this paper was to investigate diﬀerences in brain structure volumes between schizophrenia and
aﬀective psychoses, and whether cumulative lifetime antipsychotic or benzodiazepine doses relate to brain
morphology in these groups. We conducted two systematic reviews on the topic and investigated 44 schizo-
phrenia cases and 19 with aﬀective psychoses from the Northern Finland Birth Cohort 1966. The association
between lifetime antipsychotic and benzodiazepine dose and brain MRI scans at the age of 43 was investigated
using linear regression. Intracranial volume, sex, illness severity, and antipsychotic/benzodiazepine doses were
used as covariates. There were no diﬀerences between the groups in brain structure volumes. In schizophrenia,
after adjusting for benzodiazepine dose and symptoms, a negative association between lifetime antipsychotic
dose and the nucleus accumbens volume remained. In aﬀective psychoses, higher lifetime benzodiazepine dose
associated with larger volumes of total gray matter and hippocampal volume after controlling for antipsychotic
use and symptoms. It seems that in addition to antipsychotics, the severity of symptoms and benzodiazepine dose
are also associated with brain structure volumes. These results suggest, that benzodiazepine eﬀects should also
be investigated also independently and not only as a confounder.
1. Introduction
Though aﬀective psychoses are common, they are much less in-
vestigated than schizophrenia. They have been considered distinct
disease entities with diﬀering aetiology of schizophrenia, though these
psychotic disorders also share some similarities. Structural brain
changes are found in both individuals with schizophrenia (Hulshoﬀ Pol
and Kahn, 2008; Olabi et al., 2011; Vita et al., 2015) and aﬀective
psychoses (Bora et al., 2008; Busatto, 2013) when compared to con-
trols. In schizophrenia these changes include both gray and white
matter reductions (Olabi et al., 2011), especially in gray matter in the
frontal and temporal lobes, hippocampus/amygdala, thalamus and in-
sula (Shepherd et al., 2012). Though similarities can be found in the
brain structures in psychotic bipolar disorder compared to schizo-
phrenia, gray matter abnormalities and hippocampal volume reduc-
tions are more common in schizophrenia (Bora et al., 2008). Likewise,
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there are abnormalities in brain structures in psychotic depression
compared to non-psychotic depression, but less prominently than in
schizophrenia (Busatto, 2013).
The current key treatment of psychosis, regardless of its aetiology or
the underlying illness, is antipsychotic medication. Suggested harmful
eﬀects of high dose long-term antipsychotic treatment on brain struc-
ture volumes in psychoses are a debated issue with no consensus (Fusar-
Poli et al., 2013; Huhtaniska et al., 2017a). Gray matter reductions have
also been detected in populations at high risk for psychosis (Wood et al.,
2008) and drug naïve ﬁrst episode schizophrenia patients (Leung et al.,
2011), which most likely reﬂects the pathological process leading to
illness onset. However, there are some evidence from animal studies
that antipsychotic medications aﬀect brain structures even when ill-
ness-related factors are not present (Dorph-Petersen et al., 2005;
Vernon et al., 2014, 2011). In addition, as the altered morphological
ﬁndings are not present in all psychotic individuals across diagnoses, it
seems that in addition to neurodevelopmental disturbances, environ-
mental factors like medication might additionally contribute to their
origin.
According to our previous meta-analysis on long-term antipsychotic
eﬀects on brain structures, higher antipsychotic doses associated with
decrease in parietal lobe volume and increase in basal ganglia volume
(Huhtaniska et al., 2017a). A recent very large cross-sectional study
pooling data from over 4000 schizophrenia patients found associations
between medication dose and lower cortical thickness in multiple re-
gions, which persisted after controlling for negative symptom severity
(van Erp et al 2018). Many previous reviews have included both
longitudinal and cross sectional studies. In data supplement table 1 we
present previous systematic reviews on cross-sectional studies on anti-
psychotic medication eﬀects on brain structures in schizophrenia. Based
on these, higher doses of antipsychotics have been associated with
lower total brain and midbrain volumes, higher doses of typical anti-
psychotics to lower gray matter, larger basal ganglia, and larger tha-
lamic volumes, and higher doses of atypical antipsychotics to a larger
volume of caudate nucleus, thalamus, and hippocampus (Haijma et al.,
2013; Navari and Dazzan, 2009; Scherk and Falkai, 2006; Smieskova
et al., 2009).
In addition to antipsychotics, individuals with psychosis are often
medicated with other psychiatric medications, such as benzodiazepines.
When studying medication eﬀects in a non-controlled population, it is
important to take into account the possible confounding eﬀects of other
medications. To our knowledge, the eﬀect of benzodiazepine use on
brain structures has not been studied before in psychoses with the ex-
ception of our previous longitudinal study of the Northern Finland Birth
Cohort 1966 (NFBC1966) in a smaller sample (Huhtaniska et al.,
2017b). Previously benzodiazepine use has been associated with de-
cline in cognition (Baandrup et al., 2017; Fond et al., 2017) and in-
creased mortality (Fontanella et al., 2016) in schizophrenia, and de-
creased brain plasticity in mice (Curto et al., 2016; Huopaniemi et al.,
2004). Therefore, it is interesting to examine, whether there are also
eﬀects on brain structures on a macroscopic level.
The naturalistic design of our NFBC1966 data oﬀers an opportunity
to study medication eﬀects on brain structures in a population based
birth cohort setting during midlife. We are able to analyze data of in-
dividuals with psychosis several years after illness onset and several
years of treatment. We have previously published longitudinal ﬁndings
from NFBC1966 follow-up study performed at ages 34 and 43 years for
schizophrenia subjects. In these studies, higher doses of antipsychotic
medication over the follow-up was associated with a larger total brain
volume loss (Veijola et al., 2014), a degree of periventricular brain
reduction at the fourth ventricular edge (Guo et al., 2015), and an in-
crease in lateral ventricles after adjusting for symptom severity
(Huhtaniska et al., 2017b). Higher benzodiazepine doses during the
follow-up was associated with a volume decrease in the caudate nucleus
even after controlling for antipsychotic use and illness severity
(Huhtaniska et al., 2017b).
In this study, in addition to analysing associations between lifetime
antipsychotic and benzodiazepine doses and brain structures in schi-
zophrenia at early midlife, we wanted to investigate and compare
whether these medications would also associate with brain structures in
a group of individuals with aﬀective psychoses, a group that has been
studied considerably less than schizophrenia. First, we systematically
reviewed earlier literature on diﬀerences in brain morphology between
schizophrenia and aﬀective psychoses and ﬁndings regarding anti-
psychotic or benzodiazepine eﬀects on brain structures in aﬀective
psychoses. Then, our main aim was to analyse in a general population-
based sample at the age of 43 years, whether there are diﬀerences in the
brain volumes between schizophrenia and aﬀective psychoses (psy-
chotic depression or psychotic bipolar disorder) and whether lifetime
antipsychotic or benzodiazepine doses associate with brain structure
volumes when controlling for illness severity measures. The hypotheses
were that 1) individuals with schizophrenia would show larger ven-
tricular size or smaller volumes of brain structures than individuals
with aﬀective psychoses, 2) larger lifetime doses of antipsychotics and
benzodiazepines would associate with either larger ventricular size or
smaller volumes in brain structures, and 3) the eﬀect of medication
would not diﬀer between the groups.
2. Methods
2.1. Systematic reviews
To systematically review ﬁndings on structural diﬀerences in the
brain between schizophrenia and aﬀective psychoses, a literature
search was conducted the 4th of May 2017 from the database of
PubMed. We used the search terms: psychotic and (bipolar or depres-
sive or depression) and MRI and brain, and the search was directed to
human studies only. Inclusion criteria were cross-sectional design and
brain volume comparisons were made between any aﬀective psychosis
group and schizophrenia. Only studies comparing two groups with a
history of psychosis were included.
To examine previous ﬁndings regarding antipsychotic and benzo-
diazepine use and brain structures in aﬀective psychoses, a literature
search was conducted the 4th of May 2017 from the database of
PubMed. We used the search terms: psychotic and (bipolar or depres-
sive or depression or aﬀective) and (antipsychotic or benzodiazepine)
and MRI and brain and (structure or structural or morphometry), and
the search was directed to human studies only. In addition, we screened
previous reviews on topic, references of included studies and all the
included studies from the previously described search regarding dif-
ferences between brain structures in schizophrenia and aﬀective psy-
choses. Inclusion criteria was that the association between anti-
psychotic or benzodiazepine medication and brain structures was
examined in any sample of aﬀective psychosis.
2.2. Sample of NFBC1966
The participants of this study were members of the Northern
Finland Birth Cohort 1966 (NFBC1966), which is an unselected, general
population birth cohort identiﬁed during mid-pregnancy based on an
expected delivery date during 1966 in the provinces of Lapland and
Oulu, Finland. The cohort has been described in more detail in previous
publications (Husa et al., 2017; Nykänen et al., 2016). Permission to
gather data was obtained from the Ministry of Social and Health Aﬀairs
and the study design was approved by the Ethical Committee of the
Northern Ostrobothnia Hospital District.
This study is based on 63 individuals with psychosis from the
NFBC1966, who participated in the brain MRI scan, psychiatric inter-
views and examinations in 2008-2011, at an average age of 43 years
(SD 0.8), and had adequate structural MRI scans. Diagnoses were based
on information from national registers, hospital notes and SCID-I in-
terview (First et al., 2002) performed during the study at the age 43
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years (hereafter “43-year study”). The sample included 44 cases with
schizophrenia (including 2 cases with schizophreniform disorder), and
19 cases with aﬀective psychosis (including 6 cases with bipolar psy-
chosis and 13 with psychotic depression). Written informed consent
was obtained from all participants and the participants have the pos-
sibility to deny the use of their data at any time.
2.2.1. Data on use of psychiatric medication
Information on lifetime use of psychiatric medications, until the day
the person was examined in the 43-year study, was gathered by a
careful review of individual hospital, outpatient and health centre notes
of all cases from everywhere in Finland. This procedure is described in
more detail in previous publications from the NFBC1966 (Husa et al.,
2014; Moilanen et al., 2015). Current and earlier use of psychiatric
medications and their doses were ascertained in the interview at 43-
year study by asking about the use of psychiatric medications during
the previous 3 months and as far as the subjects could remember.
All medical records were reviewed to record the name of the drug,
dose and period the medication had been used. Drugs were categorized
by using the Anatomical Therapeutic Chemical (ATC) classiﬁcation
system (WHO 2011). Antipsychotics included classes N05A (anti-
psychotics) and N06CA01 (combination medicine including perphena-
zine). Benzodiazepines included classes N05BA (anxiolytics, benzodia-
zepine derivatives), N05CD (hypnotics and sedatives, benzodiazepine
derivatives), and N05CF (hypnotics and sedatives, benzodiazepine-re-
lated drugs). The information was used to calculate the cumulative dose
of lifetime medication in deﬁned daily doses (DDD) and these were then
expressed as dose-years. One DDD year (DDDy) is equivalent to using
one DDD daily for a year.
2.2.2. Covariates
As a marker of illness severity, we used Positive and Negative
Syndrome Scale (PANSS) (Kay et al., 1987), which was assessed at the
43-year study using a speciﬁc interview. The age at onset of the illness
was ascertained from medical records and it was deﬁned as the age of
ﬁrst evident psychotic symptoms. Due to the birth cohort design, age of
illness onset also reﬂects duration of illness. Sex and intracranial vo-
lume (ICV) were used as additional covariates.
2.2.3. Imaging data
The participants were scanned with the same 1.5 T GE Signa scanner
(General Electric, Milwaukee, Wisconsin) at the Oulu University
Hospital at the 43-year study. T1 weighted images were acquired with a
3D fast spoiled gradient echo (FSPGR) sequence (slice thick-
ness = 1 mm; in-plane resolution matrix size 256 × 256; voxel size
1 mm3; repetition time 12.576 ms; echo time 5.3 ms; ﬂip angle = 20°).
To extract the brain structure volumes from the MRI images we used
an online automated MRI brain volumetry system volBrain (http://
volbrain.upv.es/) (Manjón and Coupé, 2016). Based on previously re-
ported reliability measures (Huhtaniska et al., 2017b) and previous
brain imaging ﬁndings in psychoses, we selected 10 brain areas to be
examined: total brain, total gray matter (GM), cerebrum, cerebral GM,
lateral ventricles, caudate, putamen, thalamus, hippocampus, ac-
cumbens). Details on the reliability measures and image processing
pipeline are described in our previous publication (Huhtaniska et al.,
2017b) and brieﬂy in supplementary material.
2.2.4. Statistical analyses
Independent samples t-test was used to assess the diﬀerences be-
tween the background variables of the groups. Diﬀerences between
brain areas of subjects with schizophrenia and aﬀective psychoses and
associations between lifetime and medication doses and brain areas
were analysed in both groups. A logarithmic transformation was ap-
plied to medication data because of the skewness of the variables and
these were used as continuous variables in analyses. All confounders
were analysed as continuous variables.
We used several models to investigate the associations between
lifetime medication doses and brain structures in both groups. All
analyses were made using linear regression with sex and intracranial
volume (ICV) as covariates. The medication analyses were additionally
adjusted for PANSS total score and onset age. Benzodiazepine DDDy
were added as a covariate in analyses of antipsychotic DDDy, and vice
versa. In addition, we analysed the group x medication interactions in
models, where in addition to ICV, sex, group and medication dose we
included the interaction term group x medication. Corrections for
multiple comparisons were made using the Benjamini-Hochberg pro-
cedure with 10% False Discovery Rate. The analyses were performed
using IBM SPSS Statistics version 23 using p < 0.05 as a limit for sta-
tistical signiﬁcance.
3. Results
3.1. Systematic reviews
3.1.1. Diﬀerences in brain structures between schizophrenia and aﬀective
psychoses
The search located 291 studies and after abstract and title review 94
articles were evaluated in detail. The ﬁnal number of included studies
was 30. The data collection in presented in data supplement Fig 1 and
detailed information on included studies are presented in data supple-
ment Table 2.
Of the found 30 studies, 15 examined diﬀerences between schizo-
phrenia and psychotic bipolar disorder cases. Only six studies in-
vestigated diﬀerences between mixed mood disorder group and schi-
zophrenia and only two studies diﬀerences between psychotic
depression and schizophrenia. A summary of the ﬁndings of the review
is presented in Table 1. In the studies with statistically signiﬁcant
ﬁndings, the cortical volumes were smaller in the schizophrenia group
compared to aﬀective psychoses groups, and the only ﬁndings with
larger volumes in schizophrenia were found in putamen, caudate and
globus pallidus when compared to psychotic bipolar disorder (Mamah
et al., 2016; Rimol et al., 2010). Regarding lateral ventricles, the size
was larger in schizophrenia than in psychotic bipolar disorder
(McDonald et al., 2006), but larger in psychotic depression than in
schizophrenia (Salokangas et al., 2002). Of the found 30 studies, 9 did
not ﬁnd any diﬀerences between these groups in their regions of in-
terest (Cui et al., 2011; Janssen et al., 2014; Koo et al., 2008; Morgan
et al., 2007; Radonic et al., 2008; Reite et al., 2010; Rosa et al., 2010;
Rosa et al., 2015; Strasser et al., 2005).
3.1.2. Associations between antipsychotic and benzodiazepine use and
brain volumes in aﬀective psychoses
The search located 18 studies, of which 8 fulﬁlled our inclusion
criteria. In addition, 63 full text articles from other sources were in-
vestigated. In total, 71 articles were assessed in detail, and 15 studies
were included in the systematic review. The data collection is described
in data supplement Fig. 2 and detailed information on all included
studies in data supplement Table 3.
Of the 15 included studies, the majority did not ﬁnd associations
between medication and brain structures. Six studies investigated an-
tipsychotic dose eﬀects on brain structures, and seven studies anti-
psychotic status or exposure (yes/no), but none of these found any
associations. Instead, two out of four studies investigating antipsychotic
treatment duration found an association between longer duration and
morphological diﬀerences: one found an association between anti-
psychotics and positive vertex displacement in right pallidum in psy-
chotic bipolar disorder (Liberg et al., 2015), and another between
longer duration of antipsychotic exposure and increased ventricular
volumes in aﬀective psychoses but not in schizophrenia (Morgan et al.,
2007). A summary of the ﬁndings of the review is presented in Table 2.
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3.2. The NFBC1966 study
3.2.1. Characteristics of the sample
The characteristics of the sample are described in Table 3. The
schizophrenia group included more males (61%) than the aﬀective
psychoses group (32%). Only 10% of the schizophrenia group were
married/cohabited compared to the 53% in aﬀective psychoses group.
The PANSS total and subscores were higher in the schizophrenia group
Table 1
Summary of the ﬁndings in schizophrenia based on the systematic review of diﬀerences in brain volumes between schizophrenia and aﬀective psychoses.
Finding Studies
Statistically signiﬁcant ﬁndings between schizophrenia and psychotic bipolar
disorder:
- Smaller volumes in cerebellum Ivleva et al., 2012; Ivleva et al., 2013
- Gray matter deﬁcits in cerebellum Nenadic et al., 2015b
- Widespread cortical and subcortical gray matter volume reductions Brown et al., 2011; Ivleva et al., 2012; Ivleva et al., 2013; Mamah et al., 2016;
McDonald et al., 2005; Nenadic et al., 2015a, b; Salokangas et al., 2002; Harvey et al.,
1994
- Smaller cerebral gray matter volume Harvey et al., 1994
- Smaller total gray matter volume Mamah et al., 2016
- Smaller gray matter volume in subgenual cortex Yüksel et al., 2012
- Smaller hippocampal volumes Arnold et al., 2015; McDonald et al., 2006; Radonic et al., 2011; GM: Brown et al.,
2011; Nenadic et al., 2015a, b
- Larger volume of putamen Mamah et al., 2016; RImol et al., 2010
- Smaller volume of putamen Brown et al., 2011
- Diﬀerent shape of amygdala Mahon et al., 2015
- Smaller amygdala Mahon et al., 2012
- Smaller gray matter volume in amygdala Brown et al., 2011
- Larger volumes of caudate and globus pallidus Mamah et al., 2016
- Larger ventricle volumes Mc Donald et al., 2006
Statistically signiﬁcant ﬁndings between schizophrenia and schizoaﬀective
disorder
- Smaller gray matter volumes in frontotemporal, cingulate, parietal and occipital
cortices
Ivleva et al., 2012
Statistically signiﬁcant ﬁndings between schizophrenia and psychotic depression
- Smaller volume in left posterior subgenual cortex Coryel et al., 2005
- Smaller ventricular CSF volumes Salokangas et al., 2002
Statistically signiﬁcant ﬁndings between schizophrenia and combined aﬀective
psychoses group
- Smaller total brain and total gray matter volumes El-Sayed et al., 2010
- Smaller insular gray matter volume Kasai et al., 2003
- Higher rate of cavum septum pellucidum Jurjus et al., 1993
No diﬀerences between schizophrenia and psychotic bipolar disorder
- Gray matter VBM Cui et al., 2011
- Lobar cortical thickness, surface are, gyriﬁcation index and sulcal width Janssen et al., 2014
- Intracranial volume, white matter volume, nucleus accumbens and thalamic volumes Mamah et al., 2016
- Cerebral volume Mc Donald et al., 2006
- Temporal lobe volume and asymmetry Radonic et al., 2008
- Superior temporal gyrus laminar thickness Ratnanather et al., 2013
- Lateral ventricles Rosa et al., 2010
- Cortical thickness, hippocampus, amygdala, thalamus, ventricles, nucleus accumbens,
ventral diencephalon, cerebellar cortex or white matter, caudate, pallidum or
brainstem
Rimol et al., 2010
- Left hippocampus, lateral ventricles Strasser et al., 2005
No diﬀerences between schizophrenia and schizoaﬀective disorder
- gray matter VBM Ivleva et al., 2013
- Intracerebral volume, total brain volume, ventricular volume Reite et al., 2010
- Temporal lobe volume and asymmetry Radonic et al., 2008
No diﬀerences between schizophrenia and combined aﬀective psychoses group
- Frontal lobes, superior temporal cortices, hippocampus, insula, whole brain VBM Rosa et al., 2015
- Temporal pole gray matter volume Kasai et al., 2003
- VBM Morgan et al., 2007
- Cingulate gyrus gray matter volumes in 3 anterior subregions and 1 posterior
subregion
Koo et al., 2008
VBM = voxel-based morphometry.
Table 2
Summary of the systematic review of associations between medication and brain volumes in aﬀective psychoses.
Finding Studies
- Longer duration of antipsychotic exposure correlated with increased third
ventricle and lateral ventricle volumes in aﬀective psychoses group
Morgan et al., 2007
- Signiﬁcant association between antipsychotics and positive vertex
displacement in the right pallidum in psychotic bipolar disorder
Liberg et al., 2015
- No association between antipsychotic medication and investigated brain
volumes
Arnold et al., 2015; Giakoumatos et al., 2015; Ivleva et al., 2012; Ivleva et al., 2013; Janssen
et al., 2014; Kasai et al., 2003; Koo et al., 2008; Mathew et al., 2014; Rimol et al., 2010; Rosa
et al., 2010; Strakowski et al., 1999; Woodward and Heckers 2015; Yüksel et al., 2012
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and fewer individuals were in remission (21%) than in the aﬀective
psychoses group (90%). The onset age was signiﬁcantly lower in the
schizophrenia group compared to the aﬀective psychoses group. How-
ever, there were no signiﬁcant diﬀerences in educational level or the
number of people on disability pension between the groups.
There were no statistically signiﬁcant diﬀerences between brain
volumes of the two groups in any studied brain areas, see data sup-
plement Table 4.1 for details.
3.2.2. Characteristics of lifetime medication use
The characteristics of medication use in the sample are presented in
Table 4. In the schizophrenia group 42 (96%) individuals had used
antipsychotics during lifetime, and the cumulative mean dose was 20.1
DDDy. Thirty-nine (88%) individuals had used typical and 35 (80%)
individuals atypical antipsychotics. Thirty-three (75%) individuals had
used benzodiazepines (mean dose 9.1 DDDy). Thirty-two (73%) in-
dividuals had used both antipsychotics and benzodiazepines. In the
aﬀective psychoses group 15 (79%) individuals had used antipsychotics
(mean dose 3.8 DDDy). Eleven (58%) individuals had used typical and
11 (58%) individuals atypical antipsychotics. Six (32%) individuals had
used benzodiazepines (mean dose 5.8 DDDy). Five (26%) had used both
benzodiazepines and antipsychotics. All the used medications are listed
in data supplement Table 5. Many of the study subjects had used several
diﬀerent antipsychotics during their lifetime, especially those with
schizophrenia.
3.2.3. Association between lifetime cumulative antipsychotic doses and
brain volumes
In schizophrenia, higher cumulative lifetime antipsychotic doses
were associated with brain volumes in several areas (see data supple-
ment table 6 for details), and after adjusting the analyses for benzo-
diazepine use (see Table 5), the associations remained in total GM
(b = −0.25, p = 0.017), cerebral GM (b = −0.25 p = 0.024), tha-
lamus (b = −0.39 p = 0.014) and nucleus accumbens (b= -0.40,
p = 0.014). When correcting for multiple comparisons, all the asso-
ciations remained. When further examining subcortical volumes, the
associations were similar in both hemispheres with the exception of the
association between antipsychotic use and right lateral ventricle vo-
lume (see supplement Table 4.2 for details). After adding onset age to
the model, the statistically signiﬁcant associations still remained in
total GM (b = −0.26, p = 0.025), cerebral GM (b = −0.29,
p = 0.019), thalamus (b = −0.42, p = 0.016), nucleus accumbens
(b = −0.46, p = 0.011), and the lateral ventricles (b = 0.39,
p = 0.046) and all associations remained except the one in lateral
ventricles after correcting for multiple comparisons. When replacing
onset age with PANSS total score as a marker of illness severity, only
the association in nucleus accumbens remained (b = −0.38,
p = 0.033) statistically signiﬁcant, though the ﬁnding in thalamus al-
most reached signiﬁcance as well (b =−0.34, p= 0.050). However, in
the PANSS adjusted analyses, PANSS total score did not either associate
to the structure volumes with the exception of lateral ventricles
(b = 0.43, p = 0.018), which did not remain after the correction for
multiple comparisons. The results of the analyses are presented in
Table 5 and the results of further adjusted analyses in Table 6.
There were no statistically signiﬁcant associations between lifetime
antipsychotic doses and volumes of brain structures in aﬀective psy-
choses (Tables 5 and 6, data supplement Table 6).
3.2.4. Association between lifetime cumulative benzodiazepine dose and
brain volumes
In schizophrenia higher lifetime benzodiazepine doses associated
Table 3
Characteristics of the sample.
Schizophrenia
(N = 44)
Aﬀective psychoses
(N = 19)
Gender* N (%)
Male 27 (61) 6 (32)
Age at the study moment, years
Mean age (SD), range 43.1 (0.7), 41.8–44.5 43.7 (0.6),
41.9–44.4
Marital status at the study
moment* N (%)
Married or cohabiting 10 (23) 10 (53)
Single 34 (77) 9 (47)
Educational level at the study
moment N (%)
Low 24 (55) 12 (63)
Middle 10 (23) 4 (21)
High 10 (23) 3 (16)
Work status at the study
moment N (%)
Disability pension 26 (60) 9 (47)
Employed 12 (27) 7 (37)
Othera 5 (11) 2 (11)
Current alcohol abuse N (%) 4 (9) 4 (21)
Diagnosis N (%)
Schizophrenia 42 (96)
Schizophreniform disorder 2 (4)
Psychotic bipolar disorder 6 (32)
Psychotic depression 13 (68)
Lifetime hospital treatment
days*
Mean (SD) median, range 579 (899) 213,
1–5093
146 (124), 93,
2–399
PANSS mean (SD) median,
range
Total symptoms score* 70 (27), 26, 30–130 43 (11), 42, 31–75
Positive symptoms score* 17 (8) 16, 6–32 9 (3), 8, 4–16
Negative symptoms score* 19 (10) 17, 8–43 12 (4), 9, 8–21
Emotional symptoms score* 18 (7) 16, 8–33 12 (4), 10, 8–19
Excitement symptoms score* 15 (5) 14, 8–29 10 (2), 10, 8–14
Disorganized symptoms score* 25 (12) 23, 10-59 15 (7), 13, 9–36
Remission* N (%) 11 (25) 17 (90)
Onset age* mean (SD), Range 25 (6.3), 16.7–42.0 33 (5.9), 21.4–41.2
PANSS=Positive And Negative Syndrome Scale, DDD=deﬁned daily dose.
The cumulative number of hospital days since illness onset until the 43-years
study was collected from the Care Register for Health Care. Remission was
assessed using the remission criteria by Andreasen et al. (2005), and based on
PANSS interview. The symptoms were only required not to be present during
the period of one week before the assessment, and no duration criteria was used
since PANSS was done only once.
a Unemployed or not in working life due to other reasons than disability
pension.
⁎ Statistically signiﬁcant diﬀerences between the groups.
Table 4
Number of persons using antipsychotics and benzodiazepines during their
lifetime and lifetime doses of medication.
Schizophrenia (N= 44) Aﬀective
psychoses
(N = 19)
N (%a), mean DDDy
(SD)
N (%a), mean
DDDy (SD)
Use of antipsychotics in DDDy
Use of antipsychotics 42 (96), 20.1 (20.5) 15 (79), 3.8 (4.4)
Use of typical antipsychotics 39 (88), 11.3 (14.9) 11 (58), 1.0 (1.0)
Use of atypical antipsychotics 35 (80), 11.5 (9.4) 11 (58), 4.2 (4.3)
Use of benzodiazepines in
DDDy
Use of benzodiazepines 33 (75) 9.1 (10.5) 6 (32), 5.8 (8.2)
Use of benzodiazepines only
irregularly
5 (11) 1 (5)
Use of both antipsychotics and
benzodiazepines
32 (73), ap 23.5 (22.4),
bzd 9.4 (10.6)
5 (26), ap 5.2
(6.8), bzd 6.6 (8.9)
N = number of cases, SD = standard deviation, DDDy = dose years in deﬁned
daily dose, ap = antipsychotic, bzd = benzodiazepine.
a The percentage of cases that have had the medication at any point of their
illness.
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with lower volumes of total brain (b = −0.23, p = 0.002) and cere-
brum (b = −0.21, p = 0.006). After adjusting the analysis for anti-
psychotic doses, no associations remained. When onset age was added
to the model, there was again a signiﬁcant association between higher
benzodiazepine doses and lower volume of total brain (b = −0.17,
p = 0.044), but this association did not remain when adjusting for
PANSS total score instead of onset age (Tables 5 and 6, data supplement
Table 7).
In aﬀective psychoses, higher lifetime doses of benzodiazepines
were associated with larger volumes in the cerebrum (b = 0.23,
p = 0.028), total GM (b = 0.33, p = 0.021), cerebral GM (b = 0.31,
p = 0.023), thalamus (b = 0.46, p = 0.022) and hippocampus
(b = 0.56, p = 0.002) after adjusting for lifetime antipsychotic doses.
After correcting for multiple comparisons all associations remained
except the one in cerebrum. When further examining subcortical vo-
lumes, the associations were similar in both hemispheres (see supple-
ment Table 4.2 for details). After additional adjusting with onset age,
all the above mentioned associations remained. However, when ad-
justing for PANSS total score instead of onset age, only the associations
in total GM (b = 0.28, p = 0.045) and hippocampus (b = 0.48,
p = 0.007) remained. Both of these results survived the correction for
multiple comparisons. All results are presented in Tables 5 and 6 and
data supplement Table 7.
3.2.5. Interaction analyses
There were statistically signiﬁcant associations between
group × antipsychotic interaction and brain volumes in total GM and
cerebral GM. In the group × benzodiazepine interaction analyses there
were statistically signiﬁcant ﬁndings in total brain, total GM, cerebrum,
cerebral GM, thalamus and hippocampus. In all these ﬁndings, there
was a negative association in schizophrenia but positive in aﬀective
psychoses. All interaction analysis results are presented in data sup-
plement Tables 6 and 7.
4. Discussion
4.1. Main results
Based on the systematic review, the diﬀerences in brain structures
between schizophrenia and aﬀective psychoses are not clear, since
there are both studies reporting diﬀerences and no diﬀerences. The
diﬀerences are reported mainly in gray matter volumes and basal
ganglia structures.
There are no previous studies on the association between benzo-
diazepine use and brain structures in aﬀective psychoses, and of the
studies focusing on the association between antipsychotic use and brain
structures, there were only two statistically signiﬁcant ﬁndings.
Our ﬁrst hypothesis was not supported by the results, since we
found no diﬀerences in brain structure volumes at the age of 43 years
between the two diagnostic groups, even though onset age (which
corresponds to duration of illness in this sample) and illness severity
(PANSS total score) were signiﬁcantly diﬀerent between the groups.
Likewise, many earlier studies have also found no diﬀerences (Table 1).
The second hypothesis was partly supported by the results, since in
the schizophrenia group, higher cumulative lifetime antipsychotic
doses associated with smaller volumes of several areas; after adding
PANSS total score to the model, the association in nucleus accumbens
still remained, and the association in thalamus almost reached sig-
niﬁcance. Higher cumulative doses of benzodiazepines associated with
smaller volumes of total brain after controlling for antipsychotic doses
and onset age (i.e. illness duration), but the association did not remain
when adjusted for PANSS total score instead of onset age.
However, in the aﬀective psychoses group, the second hypothesis
was not supported by the results, since there were no associations be-
tween lifetime antipsychotic doses and volumes of brain structures.
Surprisingly, higher lifetime doses of benzodiazepines associated with
larger volumes in total GM and hippocampus after controlling for an-
tipsychotic dose and PANSS total score. Since the results were diﬀerent
in between the patient groups, as indicated by interaction analyses, our
third hypotheses was not supported by the results.
4.2. Antipsychotic use and brain volumes
In previous studies of an overlapping NFBC1966 sample, a higher
amount of antipsychotic medication predicted total brain volume loss
(Veijola et al., 2014) and lateral ventricular volume increase
(Huhtaniska et al., 2017b; Veijola et al., 2014), as well as periven-
tricular brain volume reductions at the fourth ventricular edge
(Guo et al., 2015) over a 9-year follow-up. In addition to brain ﬁndings,
higher doses of antipsychotics associated with decline in verbal
learning and memory (Husa et al., 2014), and high lifetime doses and
antipsychotic polypharmacy associated with poorer outcomes in schi-
zophrenia in the NFBC1966 (Moilanen et al., 2016). These previous
ﬁndings and the ﬁndings of this study are somewhat consistent and
suggest that high-dose long-term antipsychotic medications may have
some non-proﬁtable eﬀects on the brain in schizophrenia.
Our results regarding the association of antipsychotics and lower
gray matter volumes in schizophrenia are in line with the previous
review of Haijma et al. (2013). However, the ﬁndings regarding asso-
ciations between antipsychotic doses and smaller volumes in thalamus
and nucleus accumbens in schizophrenia have not been reported by
previous reviews, but instead they have reported larger volumes of the
thalamus and basal ganglia (Navari and Dazzan, 2009; Scherck and
Falkai, 2006; Smieskova et al., 2009).
Though the associations between higher lifetime doses of anti-
psychotics and brain structures in schizophrenia were confounded by
PANSS total score, the overall estimates of the models including PANSS,
sex, and ICV and antipsychotic dose, sex, and ICV were of the same
magnitude (see data supplement Table 8). Therefore, it seems, that
antipsychotics, benzodiazepines, age of illness onset or duration of
Table 5
Association between antipsychotic DDDy, benzodiazepine DDDy and brain
volumes in the same model separately in schizophrenia and aﬀective psychoses.
Sex and ICV as covariates in all analyses. Statistically signiﬁcant ﬁndings in
bold.
Antipsychotic dose and benzodiazepine in the same model
Brain area Schizophrenia
(N = 44)
Aﬀective
psychoses
(N = 19)
b p b p
Total Brain ap −0.128 0.118 0.067 0.526
bzd −0.154 0.062 0.190 0.081
Total GM ap −0.251 0.017* 0.108 0.412
bzd 0.028 0.786 0.328 0.021*
Cerebrum ap −0.134 0.125 0.086 0.384
bzd −0.138 0.115 0.233 0.028
Cerebrum GM ap −0.247 0.024* 0.132 0.306
bzd 0.044 0.682 0.314 0.023*
Lateral ventricles ap 0.325 0.061 0.027 0.913
bzd 0.064 0.699 −0.358 0.163
Caudate ap 0.002 0.990 0.373 0.081
bzd 0.121 0.471 0.201 0.324
Putamen ap 0.169 0.282 0.122 0.605
bzd 0.004 0.980 0.214 0.365
Thalamus ap −0.387 0.014* −0.176 0.345
bzd 0.005 0.971 0.458 0.022*
Hippocampus ap −0.255 0.113 −0.046 0.766
bzd −0.077 0.627 0.563 0.002*
Accumbens ap −0.396 0.014* 0.108 0.589
bzd 0.134 0.390 −0.055 0.779
ICV = intracranial volume, b = standardized beta, ap= antipsychotic,
bzd = benzodiazepine.
⁎ Statistically signiﬁcant (p < 0.05) after Benjamini-Hochberg correction.
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illnes and severity of symptoms all may have an eﬀect on brain struc-
tures.
In this study we wanted to expand the focus of antipsychotic eﬀects
also to additionally include aﬀective psychoses, in which we hypothe-
sized that the eﬀect would be similar to that of schizophrenia. Though
there were statistically signiﬁcant associations in the interaction ana-
lyses indicating that there are diﬀerential eﬀects of antipsychotics be-
tween groups, it may be due to the fact that the individuals with af-
fective psychoses in our sample had higher onset age (i.e. shorter
duration of illness) and partly because of this, the duration of medi-
cation and lifetime antipsychotic doses were much lower than in the
schizophrenia group.
Based on our systematic review, several previous studies have not
found associations between antipsychotics and brain morphology in
aﬀective psychoses (Table 2). The only positive ﬁndings regarding an-
tipsychotics and brain structures were made in studies investigating the
duration of treatment (Liberg et al., 2015; Morgan et al., 2007), which
may also be a measure of illness severity instead of measuring a pure
medication eﬀect. Though not many studies focus on aﬀective psy-
choses and antipsychotic medications, there are studies on medication
eﬀects in aﬀective disorders in general. A review on medication eﬀects
on neuroimaging ﬁndings in bipolar disorder concluded that the eﬀects
of psychotrophic medications such as lithium or antipsychotics are
predominantly normalizing and do not seem to aﬀect the diﬀerences
observed in volumes, white matter tracts or BOLD signal between bi-
polar disorder patients and healthy controls (Hafeman et al., 2012).
However, the observation of a normalizing eﬀect may also relate to
cross sectional designs or short follow-up periods of original studies,
and there is not much knowledge on long-term associations in aﬀective
disorders.
4.3. Benzodiazepine use and brain volumes
There are no previous cross-sectional studies on the association
between benzodiazepine doses or use and brain structures measured
with MRI in psychoses. In previous computed tomography studies,
benzodiazepine use has not been associated with brain volumes (Busto
et al., 2000; Lader et al., 1984; Moodley et al., 1993; Perera et al.,
1987), with the exception of an association between benzodiazepines
and increased ventricle-to-brain ratio (Schmauss and Krieg, 1987; Uhde
and Kellner, 1987). In our previous longitudinal study on NFBC1966
data including a partly overlapping sample of individuals with schizo-
phrenia, we found that higher benzodiazepine doses during the 9-year
follow-up were associated with a decrease in volume of the caudate
Table 6
Associations between antipsychotic dose, benzodiazepine dose, and total PANSS score or onset age and brain volumes in the same model separately in schizophrenia
and aﬀective psychoses. Sex and ICV as covariates in all analyses. Statistically signiﬁcant ﬁndings in bold.
Antipsychotic dose, benzodiazepine dose and PANSS in the same model Antipsychotic dose, benzodiazepine dose and onset age in the same
model
Brain area Schizophrenia (N = 44) Aﬀective psychoses (N = 19) Schizophrenia (N = 44) Aﬀective psychoses (N = 19)
Total Brain AP b = −0.078 p = 0.387 b = 0.181 p = 0.178 b = −0.165 p= 0.070 b = 0.057 p = 0.595
BZD b = −0.113 p = 0.204 b = 0.147 p = 0.173 b = −0.171 p = 0.044* b = 0.209 p = 0.070
PANSS/onset
age
b = −0.127 p = 0.163 −b = 0.195 p = 0.143 B = −0.082 p = 0.334 b = 0.092 p = 0.469
Total GM AP b = −0.171 p = 0.120 b = 0.265 p = 0.119 b = −0.263 p = 0.025* b = 0.098 p = 0.470
BZD b = 0.079 p = 0.453 b= 0.283 p= 0.045* b=0.022 p=0.831 b= 0.349 p= 0.021*
PANSS/onset
age
b =−0.202 p = =0.066 -b=0.259 p=0.120 b=−0.026 p=0.808 b=0.101 p=0.524
Cerebrum AP b= -0.073 p=0.445 b=0.179 p=0.165 b=−0.183 p=0.060 b=0.080 p=0.437
BZD b= -0.091 p=0.329 b=0.202 p=0.059 b=−0.160 p=0.075 b= 0.246 p= 0.029*
PANSS/onset
age
b= -0.157 p=0.104 −b=0.157 p=0.211 b=−0.107 = 0.237 b=0.065 p=0.588
Cerebrum GM AP b= -0.159 p=0.157 b=0.274 p=0.117 b=−0.286 p=0.019* b=0.128 p=0.342
BZD b=0.097 p=0.375 b=0.270 p=0.060 b=0.027 p=0.808 b= 0.322 p= 0.029*
PANSS/onset
age
b= -0.221 p=0.052 −b=0.229 p=0.177 b=−0.085 p=0.444 b=0.041 p=0.790
Lateral ventricles AP b=0.160 p=0.363 −b=0.212 p=0.526 b= 0.388 p= 0.046 b=0.045 p=0.860
BZD b= -0.060 p=0.725 −b=0.271 p=0.317 b=0.069 p=0.692 −b=0.394 p=0.148
PANSS/onset
age
b= 0.432 p= 0.018 b=0.443 p=0.189 b=0.137 p=0.444 −b=0.176 p=0.563
Caudate AP b=0.031 p=0.867 b=0.537 p=0.074 b=−0.078 p=0.674 b=0.344 p=0.103
BZD b=0.157 p=0.391 b=0.140 p=0.536 b=0.086 p=0.614 b=0.259 p=0.214
PANSS/onset
age
b= -0.062 p=0.738 −b=0.250 p=0.373 b=−0.175 p=0.319 b=0.286 p=0.236
Putamen AP b=0.168 p=0.324 b = 0.237 p = 0.451 b=0.008 p=0.962 b=0.136 p=0.578
BZD b= -0.033 p=0.840 b=0.195 p=0.441 b=−0.067 p=0.662 b=0.185 p=0.456
PANSS/onset
age
b= -0.022 p=0.894 −b=0.145 p=0.637 b=−0.352 p= 0.028 −b=0.139 p=0.627
Thalamus AP b= -0.336 p=0.050 −b=0.135 p=0.605 b=−0.421 p=0.016* −b=0.177 p=0.364
BZD b=0.043 p=0.794 b=0.444 p=0.050 b=−0.011 p=0.941 b= 0.460 p= 0.031
PANSS/onset
age
b= -0.111 p=0.508 −b=0.087 p=0.734 b= -0.085 p=0.592 b=0.008 p=0.971
Hippocampus AP b= -0.232 p=0.201 b=0.202 p=0.289 b = −0.317 p=0.078 −b=0.034 p=0.828
BZD b= -0.055 p=0.755 b= 0.479 p= 0.007* b= -0.105 p=0.523 b= 0.540 p= 0.005*
PANSS/onset
age
b= -0.061 p=0.734 b= -0.398p= 0.046 b=−0.136 p=0.416 −b=0.111 p=0.554
Accumbens AP b= -0.375 p= 0.033* b=0.415 p=0.071 b=−0.460 p=0.011* b=0.063 p=0.725
BZD b=0.132 p=0.430 b = 0.226 p=0.203 b=0.106 p=0.505 b=0.033 p=0.857
PANSS/onset
age
b=−0.048 p = 0.777 b=−0.517 p= 0.027 b=−0.139 p=0.393 b = 0.429 p = 0.058
ICV = intracranial volume, b = standardized beta, ap = antipsychotic, bzd = benzodiazepine.
⁎ Statistically signiﬁcant (p < 0.05) after Benjamini-Hochberg correction.
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nucleus after controlling for antipsychotic doses and PANSS average
score (Huhtaniska et al., 2017b).
In this study, lifetime benzodiazepine doses did not associate with
the volume of any brain structures in schizophrenia at the age of 43
years, when antipsychotic doses were also taken into account. In this
sample, individuals with schizophrenia had used much more anti-
psychotics (mean dose 20.1 DDDy) than benzodiazepines (mean dose
9.1 DDDy), and thus it might be hard to distinguish the eﬀect of these
two medications. Furthermore, in schizophrenia, higher lifetime ben-
zodiazepine doses may indicate a more severe illness (Takita et al.,
2016), since polypharmacy including antipsychotics and benzodiaze-
pines has been linked to poorer outcome (Längle et al., 2012).
On the other hand, in the aﬀective psychoses group, higher lifetime
benzodiazepine doses associated with larger volumes in total gray
matter and the hippocampus even after controlling for antipsychotic
dose and PANSS total score or onset age. Contrary to the schizophrenia
group, the lifetime use of antipsychotics was lower (mean dose 3.8
DDDy) than lifetime use of benzodiazepines (mean dose 5.8 DDDy),
which might partly explain this ﬁnding. The practices for prescribing
benzodiazepines might also be diﬀerent in these two patient groups
(Clark et al,. 2004).
Since there are not many studies examining the association of
benzodiazepines and brain structures, there are neither known me-
chanisms of how these medications might aﬀect brain structures.
However, in animal studies benzodiazepine exposure has been found to
decrease brain derived neurotrophic factor levels (Licata et al., 2013)
and other transcripts involved in synaptic functions and neural plasti-
city (Huopaniemi et al., 2004) and decrease the density of the spines of
pyramidal neurons (Curto et al., 2016). When considering these pre-
vious ﬁndings, our results regarding larger gray matter volumes and
higher lifetime doses are unexpected.
4.4. Function of brain areas with signiﬁcant ﬁndings
Structural alterations often cause changes in the function as well
and vice versa (Keck et al., 2011). The function of the brain areas that
were associated to antipsychotic dose in our sample are often impaired
in schizophrenia. Nucleus accumbens plays a key role in reward cir-
cuitry and action selection, integrating cognitive and aﬀective in-
formation (Floresco, 2015) and thalamus contributes to attentional
control and may associate to cognitive ﬂexibility (Halassa and
Kastner, 2017).
Larger gray matter volume has been associated with better cognitive
abilities and physical functioning (Firth et al., 2017; Fletcher et al.,
2018; Kubota et al., 2015). Though our ﬁndings are exploratory in
nature, one potential explanation behind the association between
benzodiazepine dose and larger gray matter volumes in aﬀective psy-
choses could be, that benzodiazepine use with appropriate doses may
help maintaining a better level of functioning after eliminating excess
anxiety and hence associate with greater gray matter volumes.
4.5. Strengths and limitations
This study utilizes naturalistic birth cohort data, thus the sample is
not selected and it may represent the clinical variability more realisti-
cally. In this natural setting it was possible to compare schizophrenia
cases with cases with history of aﬀective psychoses and to study both
subgroups for association of lifetime antipsychotic or benzodiazepine
doses with brain structure measurements at the age of 43 years. Our
data is very heterogenous representing diﬀerent stages of the disease
including individuals in remission, more severely ill and with active
psychosis.
To our knowledge, there are no other studies with data on lifetime
use of antipsychotics and benzodiazepines in individuals with schizo-
phrenia or aﬀective psychoses. The medication data has been collected
very comprehensively by scrutinizing all available medical records and
interviewing all subjects carefully at the time of the study.
The main limitation of this study is the small sample size and the
diﬀerent number of cases in patient groups. Especially the number of
medicated cases is limited in the aﬀective psychoses group.
Acknowledging the small sample size and that there are no previous
studies on topic regarding benzodiazepine eﬀects on brain volumes,
there is a possibility that our ﬁndings may be by chance and the results
must be interpreted with caution and considered exploratory and hy-
pothesis generating rather than being conclusive. However, the ﬁndings
regarding schizophrenia cases are in line with our previous longitudinal
studies (Guo et al., 2015; Huhtaniska et al., 2017b; Veijola et al., 2014).
The diﬀerences in background variables may also aﬀect our results.
The gender distribution was signiﬁcantly diﬀerent between the groups:
in the aﬀective psychoses 68% of the subjects were female vs. 39% in
the schizophrenia group. In addition, the diﬀerences in marital status,
age at illness onset, and severity of illness between the groups may
aﬀect the results. There were also diﬀerences in the background vari-
ables between the groups that we could not control for in our analyses
due to lack of power. We had no data on symptom severity covering the
whole illness course, which could have provided a more reliable mea-
sure of illness severity. We were not able to study or take into account
the use of other treatment methods such as psychosocial treatments or
ECT due to lack of data. In addition we were unable to study or control
for persistent anxiety and insomnia, which may lead to long-term
treatment with benzodiazepines and could potentially confound our
results. The lack of a healthy comparison group is also a limitation.
The cross-sectional design cannot answer the question whether
there is an actual change in the brain structure volumes associated to
medication, but unfortunately we do not have longitudinal data on
brain changes in aﬀective psychoses, though we have reported long-
itudinal ﬁndings in schizophrenia cases from this sample
(Huhtaniska et al., 2017b). However, it could be presumed, that if these
medications associate to brain structures in a longitudinal design, we
would also detect associations when examining lifetime medication
exposure in a cross sectional design. In addition, it is unfortunate, that
we were not able to examine cortical volumes in detail, since our
imaging data did not allow it, and thus it is possible, that cortical vo-
lume ﬁndings were left undetected.
Though the medication data was collected very thoroughly, we
cannot exclude the potential confounding eﬀects of other psychotropic
or somatic medications, such as antidepressants or mood stabilizers.
Especially the use of lithium could confound the results, but since in
this sample there were no subjects that had used lithium during their
whole lifetime, there was no need to take it into account. Unfortunately
we didn't have data for other life-time mood stabilizer use. However, at
the time of the study, seven cases with schizophrenia and ﬁve with
aﬀective psychoses used mood stabilizers. In addition, many individuals
had used several diﬀerent antipsychotics including both typical and
atypical medications, and we could not study separately the eﬀects of
independent drugs.
4.6. Conclusions
Our ﬁndings underline the importance of taking benzodiazepine use
and illness severity measures into account when studying antipsychotic
eﬀects on the brain. Since the detected eﬀects between lifetime ben-
zodiazepine dose and brain volumes were moderate in size, the eﬀect
should be studied further in larger populations to check if our ﬁndings
are true, by chance, or explained by factors we were not able to control
for. In addition, more studies focusing on aﬀective psychoses and
medication eﬀects on brain structures are necessary. Further studies
should also focus on how these ﬁndings correspond to cognition and
functioning.
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